Evidence map›Paper›PMID 40076809›Full record

ArticleInternational journal of molecular sciences2025

Plasma miR-145-5p Levels and Risk of Future Cancer-Results from the HUNT Study.

Christopher Antoun, Julia Oto, Vânia M Morelli, Kristian Hveem, Sigrid K Brækkan, Pilar Medina, John-Bjarne Hansen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christopher AntounThrombosis Research Group (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, 9019 Tromsø, Norway.ORCID 0009-0002-2966-2027
Julia OtoHaemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe, 46026 Valencia, Spain.
Vânia M MorelliThrombosis Research Group (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, 9019 Tromsø, Norway.
Kristian HveemHUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Sigrid K BrækkanThrombosis Research Group (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, 9019 Tromsø, Norway.
Pilar MedinaHaemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Health Research Institute Hospital La Fe, 46026 Valencia, Spain.ORCID 0000-0001-9637-5998
John-Bjarne HansenThrombosis Research Group (TREC), Department of Clinical Medicine, UiT-The Arctic University of Norway, 9019 Tromsø, Norway.

Funding

Kristian Gerhard Jebsen Foundation SKGJ-MED-012
6 · The paper itself

Abstract

MicroRNA-145-5p (miR-145) has been reported to regulate multiple oncogenes and is considered a tumor suppressor. However, it remains unknown whether the level of plasma miR-145 can serve as a risk biomarker for future cancer. Using a population-based cohort (

Indexed as

Biomarkers, TumorMicroRNAsNeoplasmsAdultAgedFemaleHumansMaleMiddle AgedProportional Hazards ModelsRisk FactorsBiomarkers, TumorMicroRNAsMIRN145 microRNA, humanbiomarkerscancercohort studiesfollow-up studiesmicroRNAsproportional hazards models

Identifiers

PMID40076809
PMCPMC11899732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.